62 related articles for article (PubMed ID: 24215674)
1. Novel synthetic oleanane triterpenoid AMR-MeOAc inhibits K-Ras through ERK, Akt and survivin in pancreatic cancer cells.
Rabi T; Venkatanarashiman M
Phytomedicine; 2014 Mar; 21(4):491-6. PubMed ID: 24215674
[TBL] [Abstract][Full Text] [Related]
2. Multiple mechanisms involved in a low concentration of FL118 enhancement of AMR-MeOAc to induce pancreatic cancer cell apoptosis and growth inhibition.
Rabi T; Li F
Am J Cancer Res; 2018; 8(11):2267-2283. PubMed ID: 30555743
[TBL] [Abstract][Full Text] [Related]
3. Aphanin, a triterpenoid from Amoora rohituka inhibits K-Ras mutant activity and STAT3 in pancreatic carcinoma cells.
Rabi T; Catapano CV
Tumour Biol; 2016 Sep; 37(9):12455-12464. PubMed ID: 27333990
[TBL] [Abstract][Full Text] [Related]
4. Nicotinamide prohibits proliferation and enhances chemosensitivity of pancreatic cancer cells through deregulating SIRT1 and Ras/Akt pathways.
Zhang JG; Zhao G; Qin Q; Wang B; Liu L; Liu Y; Deng SC; Tian K; Wang CY
Pancreatology; 2013; 13(2):140-6. PubMed ID: 23561972
[TBL] [Abstract][Full Text] [Related]
5. Down-regulation of the nuclear factor-kappaB by lidamycin in association with inducing apoptosis in human pancreatic cancer cells and inhibiting xenograft growth.
Chen J; Ouyang ZG; Zhang SH; Zhen YS
Oncol Rep; 2007 Jun; 17(6):1445-51. PubMed ID: 17487403
[TBL] [Abstract][Full Text] [Related]
6. Lupeol, a fruit and vegetable based triterpene, induces apoptotic death of human pancreatic adenocarcinoma cells via inhibition of Ras signaling pathway.
Saleem M; Kaur S; Kweon MH; Adhami VM; Afaq F; Mukhtar H
Carcinogenesis; 2005 Nov; 26(11):1956-64. PubMed ID: 15958516
[TBL] [Abstract][Full Text] [Related]
7. Recombinant expression of different mutant K-ras gene in pancreatic cancer Bxpc-3 cells and its effects on chemotherapy sensitivity.
Shao T; Zheng Y; Zhao B; Li T; Cheng K; Cai W
Sci China Life Sci; 2014 Oct; 57(10):1011-7. PubMed ID: 25216706
[TBL] [Abstract][Full Text] [Related]
8. Identification of a small molecule with synthetic lethality for K-ras and protein kinase C iota.
Guo W; Wu S; Liu J; Fang B
Cancer Res; 2008 Sep; 68(18):7403-8. PubMed ID: 18794128
[TBL] [Abstract][Full Text] [Related]
9. Downregulation of survivin and activation of caspase-3 through the PI3K/Akt pathway in ursolic acid-induced HepG2 cell apoptosis.
Tang C; Lu YH; Xie JH; Wang F; Zou JN; Yang JS; Xing YY; Xi T
Anticancer Drugs; 2009 Apr; 20(4):249-58. PubMed ID: 19174695
[TBL] [Abstract][Full Text] [Related]
10. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.
Ulivi P; Arienti C; Amadori D; Fabbri F; Carloni S; Tesei A; Vannini I; Silvestrini R; Zoli W
J Cell Physiol; 2009 Jul; 220(1):214-21. PubMed ID: 19288493
[TBL] [Abstract][Full Text] [Related]
11. Synthesis of novel ursolic acid heterocyclic derivatives with improved abilities of antiproliferation and induction of p53, p21waf1 and NOXA in pancreatic cancer cells.
Leal AS; Wang R; Salvador JA; Jing Y
Bioorg Med Chem; 2012 Oct; 20(19):5774-86. PubMed ID: 22959527
[TBL] [Abstract][Full Text] [Related]
12. Molecular target-based therapy of pancreatic cancer.
Lebedeva IV; Sarkar D; Su ZZ; Gopalkrishnan RV; Athar M; Randolph A; Valerie K; Dent P; Fisher PB
Cancer Res; 2006 Feb; 66(4):2403-13. PubMed ID: 16489047
[TBL] [Abstract][Full Text] [Related]
13. Esophageal cancer exhibits resistance to a novel IGF-1R inhibitor NVP-AEW541 with maintained RAS-MAPK activity.
Bao XH; Takaoka M; Hao HF; Wang ZG; Fukazawa T; Yamatsuji T; Sakurama K; Sun DS; Nagasaka T; Fujiwara T; Naomoto Y
Anticancer Res; 2012 Jul; 32(7):2827-34. PubMed ID: 22753744
[TBL] [Abstract][Full Text] [Related]
14. Survivin expression is regulated by coexpression of human epidermal growth factor receptor 2 and epidermal growth factor receptor via phosphatidylinositol 3-kinase/AKT signaling pathway in breast cancer cells.
Asanuma H; Torigoe T; Kamiguchi K; Hirohashi Y; Ohmura T; Hirata K; Sato M; Sato N
Cancer Res; 2005 Dec; 65(23):11018-25. PubMed ID: 16322251
[TBL] [Abstract][Full Text] [Related]
15. A small molecule compound inhibits AKT pathway in ovarian cancer cell lines.
Tang HJ; Jin X; Wang S; Yang D; Cao Y; Chen J; Gossett DR; Lin J
Gynecol Oncol; 2006 Feb; 100(2):308-17. PubMed ID: 16209885
[TBL] [Abstract][Full Text] [Related]
16. Potent inhibition of small-cell lung cancer cell growth by simvastatin reveals selective functions of Ras isoforms in growth factor signalling.
Khanzada UK; Pardo OE; Meier C; Downward J; Seckl MJ; Arcaro A
Oncogene; 2006 Feb; 25(6):877-87. PubMed ID: 16170339
[TBL] [Abstract][Full Text] [Related]
17. Mutations in K-Ras linked to levels of osteoprotegerin and sensitivity to TRAIL-induced cell death in pancreatic ductal adenocarcinoma cells.
Kanzaki H; Ohtaki A; Merchant FK; Greene MI; Murali R
Exp Mol Pathol; 2013 Apr; 94(2):372-9. PubMed ID: 23219833
[TBL] [Abstract][Full Text] [Related]
18. Combined silencing of K-ras and Akt2 oncogenes achieves synergistic effects in inhibiting pancreatic cancer cell growth in vitro and in vivo.
Shi XH; Liang ZY; Ren XY; Liu TH
Cancer Gene Ther; 2009 Mar; 16(3):227-36. PubMed ID: 18949011
[TBL] [Abstract][Full Text] [Related]
19. Ziyuglycoside II induces cell cycle arrest and apoptosis through activation of ROS/JNK pathway in human breast cancer cells.
Zhu X; Wang K; Zhang K; Zhu L; Zhou F
Toxicol Lett; 2014 May; 227(1):65-73. PubMed ID: 24680927
[TBL] [Abstract][Full Text] [Related]
20. The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a RAS-dependent manner.
Chakravarti A; Chakladar A; Delaney MA; Latham DE; Loeffler JS
Cancer Res; 2002 Aug; 62(15):4307-15. PubMed ID: 12154034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
